Thomas M Deutsch
Overview
Explore the profile of Thomas M Deutsch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goerdt L, Stefanovic A, Wirtz R, Karic U, Kohler M, Deutsch T, et al.
In Vivo
. 2025 Feb;
39(2):758-765.
PMID: 40010968
Background/aim: Class 1 human leukocyte antigen (HLA) ensures that cytotoxic T lymphocytes (CTLs) attack tumor cells. As part of tumor de-differentiation, the expression of HLA on the tumor cell surface...
2.
Bartkowiak K, Mohammadi P, Nissen P, Werner S, Agorku D, Andreas A, et al.
Sci Rep
. 2025 Jan;
15(1):3913.
PMID: 39890941
Cell lines derived from circulating tumor cells (CTCs) in the blood provide important biological information on cancer metastasis. CTC-ITB-01 is a CTC cell line derived from a patient with metastatic...
3.
Goerdt L, Stefanovic A, Wirtz R, Karic U, Deutsch T, Kohler M, et al.
Anticancer Res
. 2025 Jan;
45(2):445-450.
PMID: 39890193
Background/aim: The loss of breast cancer cell differentiation during metastatic progression leads to a down-regulation of class 1 human leukocyte antigen (HLA) expression, which in turn hinders cytotoxic T lymphocytes...
4.
Cai L, Deutsch T, Sidey-Gibbons C, Kobel M, Riedel F, Smetanay K, et al.
JCO Clin Cancer Inform
. 2024 Dec;
8:e2400010.
PMID: 39715466
Purpose: Toxicity to systemic cancer treatment represents a major anxiety for patients and a challenge to treatment plans. We aimed to develop machine learning algorithms for the upfront prediction of...
5.
Tretschock L, Clemente H, Smetanay K, Fremd C, Thewes V, Hassdenteufel K, et al.
Oncol Res Treat
. 2024 Nov;
1-11.
PMID: 39608321
Introduction: Significant progress has been made in the targeted therapy of metastatic breast cancer (mBC) in recent years. In this context, new biomarkers enable personalized therapy management and individualized therapy...
6.
Horn A, Wendel J, Franke I, Bauer A, Baumeister H, Bendig E, et al.
Trials
. 2024 Nov;
25(1):767.
PMID: 39543763
Background: The risk of breast cancer patients for long-term side effects of therapy such as neurotoxicity and cardiotoxicity as well as late effects regarding comorbidities varies from individual to individual....
7.
Anders C, Moorthy P, Svensson L, Muller J, Heinze O, Knaup P, et al.
JMIR Hum Factors
. 2024 Mar;
11:e50926.
PMID: 38441959
Background: Early identification of quality of life (QoL) loss and side effects is a key challenge in breast cancer therapy. Digital tools can be helpful components of therapeutic support. Enable,...
8.
Deutsch T, Fischer C, Riedel F, Hassdenteufel K, Michel L, Sutterlin M, et al.
Arch Gynecol Obstet
. 2023 Jul;
309(1):235-248.
PMID: 37480379
Background: The proliferation marker Ki-67 is a major pathological feature for the description of the state of disease in breast cancer. It helps to define the molecular subtype and to...
9.
Deutsch T, Pfob A, Brusniak K, Riedel F, Bauer A, Dijkstra T, et al.
Eur J Cancer
. 2023 May;
188:111-121.
PMID: 37229835
Background: Assessments of health-related quality of life (HRQoL) play an important role in transition to palliative care for women with metastatic breast cancer. We developed machine learning (ML) algorithms to...
10.
Stefanovic S, Wirtz R, Sutterlin M, Karic U, Schneeweiss A, Deutsch T, et al.
Anticancer Res
. 2023 Mar;
43(4):1449-1454.
PMID: 36974778
Background/aim: Loss of differentiation of breast cancer cells in association with a down-regulated class I human leukocyte antigen (HLA) expression can lead to proliferation unhampered by cytotoxic T lymphocytes, which...